Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
Int J Cancer. 2021 Sep 15;149(6):1313-1321. doi: 10.1002/ijc.33695. Epub 2021 May 27.
Int J Cancer. 2021.
PMID: 34019700
Free article.
Clinical Trial.
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.
Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL.
Mazorra Z, et al. Among authors: lugiollo m.
Front Pharmacol. 2017 Jun 19;8:382. doi: 10.3389/fphar.2017.00382. eCollection 2017.
Front Pharmacol. 2017.
PMID: 28674498
Free PMC article.
Item in Clipboard
Cite
Cite